1. Most Discussed
  2. Gainers & Losers
  1. Members, Techs apologise for the loss of thread titles, and are currently working on restoring them. They will be back asap. Thank you
POH 1.8¢

New review of neuropathic pain therapies

  1. hottod

    3,225 Posts.
    A systematic review and meta-analysis of pharmacotherapy for neuropathic pain has been published in The Lancet Neurology (February 2015).

    229 studies (196 published and 33 unpublished) were included in the meta-analysis. Analysis of publication bias suggested a 10% overstatement of treatment effects. It was found that neuropathic pain trial outcomes were generally modest and placebo responses were typically high.

    On balance, tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors, pregabalin, and gabapentin were recommended as first-line treatments. On average, approximately one in seven patients experienced 50% pain relief using these therapies.

    Lidocaine patches (found to have limited evidence) along with capsaicin patches and tramadol were recommended as second-line treatments.

    Among their findings, the authors noted that tolerability and safety, and values and preferences were higher for topical therapies.

    In a linked commentary, Dr David Bennett, Professor of Neurology and Neurobiology at Oxford University said “Overall, present options are far from ideal and new and more efficacious treatments than exist at present are needed for neuropathic pain.”



Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.


Thank you for visiting HotCopper

We have detected that you are running ad blocking software.

HotCopper relies on revenue generated from advertisers. Kindly disable your ad blocking software to return to the HotCopper website.

I understand, I have disabled my ad blocker. Let me in!

Need help? Click here for support.